Strike Pharma
- Biotech or pharma, therapeutic R&D
Targeted delivery of nanoparticles for in vivo CAR T therapy
Strike Pharma has developed a technology platform for targeted delivery of nanoparticles, enabling generation of in vivo CAR-T therapies. The technology is based on a binder (scFv) with ultra-high affinity for 9-mer synthetic peptide tag (≤30 pM). Integration of peptide tag with lipid nanoparticles (LNPs) allows adaptive binding of LNPs to T-cell targeting antibody fragments, enabling targeted delivery of CAR mRNA complex to T cells. A lead anti-CD19 in vivo CAR-T is in preclinical development for lymphoma and autoimmune disease.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}